A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

Published:2024-03 Issue: Volume:182 Page:124-131
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Cristea Mihaela C.,Stewart Daphne,Synold Timothy,Ruel Nora,Mortimer Joanne,Wang Edward,Jung Alexander,Wilczynski Sharon,Konecny Gottfried E.,Eng Melissa,Kilpatrick Lindsay,Han Ernest,Dellinger Thanh,Hakim Amy,Lee Stephen,Morgan Robert J.,Wakabayashi Mark T.,Frankel Paul H.

Publisher

Elsevier BV

Reference21 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies;Tarantino;CA Cancer J. Clin.,2022

3. Exploiting the folate receptor α in oncology;Scaranti;Nat. Rev. Clin. Oncol.,2020

4. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy;Despierre;Gynecol. Oncol.,2013

5. ELAHERE Package Insert,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature;Gynecologic Oncology Reports;2024-10

2. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer;Cancers;2024-07-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP